Nepal plane crash: Over 50 killed, PM Modi, US offer condolences

Singapore, Jul 11: Singapore Prime Minister Lee Hsien Loong has secured a “clear mandate” with his ruling People’s Action Party (PAP) winning 83 of the 93 contested parliamentary seats in the general election held amidst the Covid-19 pandemic, with the Opposition gaining ground by winning a record 10 seats.

The ruling party, in power since independence in 1965, secured 61.24 percent of the total votes cast in the election, down from 69.9 percent in 2015. About 2.6 million Singaporeans voted on Friday.

“We have a clear mandate, but the percentage of the popular vote is not as high as I had hoped for,” 68-year old Lee told a PAP’s post-results press conference on Saturday morning.

The opposition Workers’ Party secured 10 seats and defeated a team in the Group Representation Constituency of Sengkang led by former Minister in the Prime Minister’s Office Ng Chee Meng who is also the Secretary-General of the power National Trades Union Congress (NTUC).

The Prime Minister assured it is “only right” that Workers’ Party’s Indian-origin secretary-general Pritam Singh be “formally designated” as the Leader of the Opposition, and that he will be provided with “appropriate staff support and resources to perform his duties”.

Lee took the results in “these circumstances” as an “endorsement” of the party’s policies and plans as he had called the elections amidst Covid-19 pandemic.

For latest updates and live news on coronavirus, click here

“We’ll take this forward and work with Singapore to realise those plans and solve the problems which we have,” Channel News Asia quoted the premier as saying.

Lee, who leads the PAP as secretary-general, said, “Singaporeans understand what’s at stake and why we must come together to uphold our national interests.”

He pledged to use this mandate “responsibly” to deal with the Covid-19 situation and economic downturn, to take Singapore “safely through the crisis and beyond”.

“The results reflect the pain and uncertainty that Singaporeans feel in this crisis, the loss of income, the anxiety about jobs, the disruption caused by the circuit breaker and the safe distancing restrictions,” he said.

This was not a “feel-good” election, said Lee, Singapore’s third prime minister who faces the city state’s worst recession with the economy projected to shrink between 7 and 4 per cent.

Lee acknowledged that the result also showed a “clear desire” for a diversity of voices in Parliament.

“Singaporeans want the PAP to form the government, but they, and especially the younger voters, also want to see more opposition presence in parliament,” he noted.

Lee added that he looks forward to the participation and contribution of the Opposition in parliament.

Singh, whose Workers’ Party team retained Aljunied Group Representation Constituency (GRC), will have 10 elected MPs now, up from six previously. His fellow member also retained the Hougang single-member constituency seat.

“Whether it works out… and whether it’s seen as a strengthening of Singapore will depend not only on what the PAP does but also on what the Opposition does because the Opposition now has 10 MPs elected from constituencies,” said Lee.

He assured that the ruling party will listen to Singaporeans and do its best to address their concerns, and “try to win” their support, whether or not they voted for the PAP.

When asked by the media if the party had lost the youth vote, he noted that different generations have different life experiences, and the young have significantly different life aspirations and priorities compared to the older generations.

“That’ll have to be reflected in our political process and in the government’s policies because, in the end, the government’s policies must be to achieve the aspirations of every generation of Singaporeans,” Lee said, assuring Singaporeans.

He hoped that the new generations of Singaporeans “look critically, but with an open mind” at what previous generations have done, “examine what’s relevant and what continues to make sense to them in a new environment” and “learn from these experiences hard-won by their parents and grandparents”.

This is so that they do not have to “learn them all over again and pay a high price which has already been paid”.

Lee added that he was, naturally, disappointed at the loss of the newly formed Sengkang GRC, which the Workers’ Party won with 52.13 percent of the valid votes.

“Ng Chee Meng and his team -- Lam Pin Min, Amrin Amin and Raymond Lye -- always knew it was going to be a tough fight,” he said.

“They gave it their all, but Sengkang voters have spoken, and we respect their decision.”

Lee described it as a “major loss to my team” and to the fourth-generation leaders, especially as Ng is the secretary-general of the Labour Movement, the NTUC.

Singh, 43, told a press conference following the results that his team would “continue to endeavour for good outcomes on the ground” and to represent voters “faithfully in parliament”.

“Today’s results are positive, but we have to hit the ground running. We should not get over our head with the results. There’s much work to do. And I can assure you this Workers’ Party team is committed to serve Singapore,” he stressed.

The PAP contested all 93 seats and the Workers’ Party 21 seats. Nine other political parties also contested the elections.

A total of 192 candidates contested for seats through 17 Group Representation Constituencies (GRCs).

Washington, May 19: As the scientists across the world are struggling to develop a vaccine for combating coronavirus, US drugmaker Moderna announced on Monday (local time) that the phase I trial of its Covid-19 vaccine has shown positive early results.

The company is hopeful that it's vaccine could be available to the public as early as January next year. Several firms across the world are in the race to develop a vaccine for the deadly virus which has claimed over 3 lakh lives worldwide.

CNN citing Dr. Tal Zaks, Moderna's chief medical officer reported that "if future studies go well, the company's vaccine could be available to the public as early as January".

"This is absolutely good news and news that we think many have been waiting for for quite some time," Zaks was quoted as saying.

Moderna, based in Cambridge, Massachusetts announced that the vaccine developed neutralising antibodies to the virus at levels reaching or exceeding the levels seen in people who have naturally recovered from Covid-19, reported CNN.

These will be followed by phase 2 trials and phase 3 trials, which Moderna plans to start in July.

President Donald Trump had on Friday said that that the United States will be able to deliver a few hundred million doses of COVID-19 vaccine, under 'Operation Warp Speed', by the end of this year.

"I have very recently seen early data from a clinical trial with a coronavirus vaccine and this data made me feel even more confident that we'll be able to deliver a few hundred million doses of vaccine by the end of 2020 and we will do the best we can," Trump had said at a press conference at the White House on Friday.

Beijing/Zurich, Mar 4: China has approved the use of Swiss drugmaker Roche's anti-inflammation drug Actemra for patients who develop severe complications from the coronavirus as it urgently hunts for new ways to combat the deadly infection that is spreading worldwide.

China is hoping that some older drugs could stop severe cytokine release syndrome (CRS), or cytokine storms, an overreaction of the immune system which is considered a major factor behind catastrophic organ failure and death in some coronavirus patients.

Actemra, a biologic drug approved in 2010 in the United States for rheumatoid arthritis (RA), inhibits high Interleukin 6 (IL-6) protein levels that drive some inflammatory diseases.

China's National Health Commission said in treatment guidelines published online on Wednesday that Actemra can now be used to treat coronavirus patients with serious lung damage and high IL-6 levels.

Separately, researchers in the country are testing Actemra, known generically as tocilizumab, in a clinical trial expected to include 188 coronavirus patients and running until May 10.

Roche, which donated 14 million yuan ($2.02 million) worth of Actemra during February, said the trial was initiated independently by a third party with the aim of exploring the efficacy and safety of the drug in coronavirus patients with CRS.

It added that there was currently no published clinical trial data on the drug's safety or efficacy against the virus.

More than 3,000 people have died and 93,000 have been infected by the novel coronavirus thought to have originated in Wuhan, China, before spreading to around 90 countries including the United States, Italy, Switzerland, France and Germany.

The Swiss company, for which China is its No. 2 market behind the United States, also makes diagnostic gear to detect the coronavirus.

Since Actemra's approval a decade ago, it has become a go-to drug against other inflammatory conditions, including cytokine storms in cancer patients receiving cell therapies from Novartis and Gilead Sciences.

In 2012 it helped save the life of a young U.S. girl, the first child to be treated for leukaemia with Novatis' Kymriah, from a post-treatment rush of IL-6.

Priced at between $20-30,000 annually for RA according to SSR Health, Roche's medicine is also used for rare juvenile arthritis and giant cell arteritis, or inflammation of the blood vessels.